Several factors have been identified that may predict super response or refractory response to rituximab among patients with pemphigus.

Please provide your email address to receive an email when new articles are posted on . Results of a study showed that antirituximab antibodies are common among patients with pemphigus who have been ...

Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line ...

PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

Please provide your email address to receive an email when new articles are posted on . Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but ...

Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases. The National Institutes of Health has begun a clinical trial to ...